يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"Everolimus/therapeutic use"', وقت الاستعلام: 0.61s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Gonzalo Sapisochin, Wei Chen Lee, Dong Jin Joo, Jae-Won Joh, Koichiro Hata, Arvinder Singh Soin, Uday Kiran Veldandi, Shuhei Kaneko, Matthias Meier, Denise Leclair, Gangadhar Sunkara, Long Bin Jeng, Joo, Dong Jin

    العلاقة: ANNALS OF TRANSPLANTATION; J00184; OAK-2022-09556; https://ir.ymlib.yonsei.ac.kr/handle/22282913/192952Test; T202300208; ANNALS OF TRANSPLANTATION, Vol.27 : e937988, 2022-11

  2. 2
    دورية أكاديمية
  3. 3

    المساهمون: Internal medicine, Medical oncology, CCA - Cancer biology and immunology, AII - Cancer immunology, Medical oncology laboratory, Academic Medical Center

    المصدر: Werter, I M, Huijts, C M, Lougheed, S M, Hamberg, P, Polee, M B, Tascilar, M, Los, M, Haanen, J B A G, Helgason, H H, Verheul, H M, de Gruijl, T D, van der Vliet, H J & Dutch WIN-O Consortium 2019, ' Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus ', Cancer Immunology, Immunotherapy, vol. 68, no. 5, pp. 787-798 . https://doi.org/10.1007/s00262-019-02313-zTest
    Cancer Immunology, Immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
    Cancer Immunology Immunotherapy, 68, 5, pp. 787-798
    Cancer immunology, immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
    Cancer Immunology Immunotherapy, 68, 787-798

    وصف الملف: application/pdf